Boehringer Ingelheim:ベーリンガー、がん免疫治療のスタートアップ買収
独製薬大手の独ベーリンガー・インゲルハイムは15日、がん免疫治療薬の開発を手がけるスイスのスタートアップ企業AMALセラピューティクスを買収すると発表した。治療が困難なタイプの胃がん、腸がん、肺がん分野で製品ポートフォリ […]
独製薬大手の独ベーリンガー・インゲルハイムは15日、がん免疫治療薬の開発を手がけるスイスのスタートアップ企業AMALセラピューティクスを買収すると発表した。治療が困難なタイプの胃がん、腸がん、肺がん分野で製品ポートフォリ […]
Cookie | 期間 | 説明 |
---|---|---|
cookielawinfo-checbox-analytics | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics". |
cookielawinfo-checbox-functional | 11 months | The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional". |
cookielawinfo-checbox-others | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other. |
cookielawinfo-checkbox-necessary | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary". |
cookielawinfo-checkbox-performance | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance". |
viewed_cookie_policy | 11 months | The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data. |